Interview: William Yim – Executive Chairman and CTO ; Kelvin Chiu – CEO, Sanwa Biotech, Hong Kong

12.07.2017
William Yim and Kelvin Chiu of Sanwa Biotech discuss their innovative company’s impressive growth and the environment for biotech start-up companies in Hong Kong. Despite only having been founded five years ago in 2012, Sanwa BioTech has seen tremendous progress. Can you highlight some of the main development milestones?
"Our product model is tuned for personalized care on specific POCT needs, and operates more like an espresso machine: the technology is set but there are different 'flavors'."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Hong Kong, China, Senwa Biotech, Biotech, Startup, Strategy, Innovation

Related Interviews

Alex Zhavoronkov – CEO, Insilico Medicine

Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative…

Alex Wong – CEO, Xcelom

Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong…

Albert Yu – Chairman, Hong Kong Biotechnology Organization (HKBIO)

Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning…

Related Articles

Hong Kong / HKEX Continues Biotech Momentum in Q3 2021

Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.…

China / Sinopharm Looks to mRNA Vaccines; Hong Kong Biotech Investment Continues to Boom; Another Big Manufacturing Investment for Lonza

The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its own mRNA vaccine; an update on Hong Kong’s biotech investment ecosystem three year…

Hong Kong / HKEX Biotech IPOs in the First Half of 2021

Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has become Asia’s largest, and the world’s second-largest,…

Latest Report

Switzerland Pharma Report June 2021

Related Content

Hong Kong
China
Senwa Biotech
Biotech
Startup
Strategy
Innovation